Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

I am a UK healthcare professional No, take me back
UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY
Trimbow® for Moderate to Severe COPD Overview

Dosing & Device

Costing

Evidence

Prescribing Information

General Resources

Request a Representative

Prescribing Trimbow®

Each dose contains three established molecules for the maintenance treatment of your adult patients with moderate to severe COPD not adequately treated with ICS/LABA or LABA/LAMA who require triple therapy1,2

Each metered dose contains:1,2

  • 100 mcg beclometasone
  • 6 mcg formoterol
  • 10 mcg glycopyrronium

 

Each delivered dose contains:1,2

26343 Trimbow NEXThaler HCP Web Assets NEXThaler v2
26343 Trimbow NEXThaler HCP Web Assets NEXThaler
The delivered dose is the dose leaving the mouthpiece and the metered dose is the dose leaving the valve.

Trimbow contains beclometasone, formoterol and glycopyrronium in a solution or dry powder formulation resulting in an aerosol with extrafine particles.1,2

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 offers twice-daily dosing, which is familiar to many patients1 -3

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2

Two puffs in the morningTwo puffs in the evening

Trimbow pMDI 87/5/9 is licensed for use with an AeroChamber Plus® spacer[[1]]

As a pMDI, Trimbow 87/5/9 has the option to be used with an AeroChamber Plus® spacer.1

  • Patients already familiar with a pMDI + spacer can use the same inhalation technique with Trimbow pMDI 87/5/91,4
  • The option of using Trimbow pMDI 87/5/9 with an AeroChamber Plus® spacer can reduce oropharyngeal deposition and assist with hand-breath coordination1,5

Trimbow device with an AeroChamber Plus attached

Dose counter

Inclusion of a dose counter means patients can keep track of their remaining Trimbow doses at any time.1,2

Trimbow device with close up on the dose counter

NEXThaler device

Trimbow NEXThaler 88/5/9’s inhalation counter and audible ‘click’ can help to reassure patients that they have successfully inhaled their medication.2

Regardless of COPD severity, 100% of patients in an open-label, single-arm study had successful inhalation with a placebo NEXThaler. Patients with COPD aged ≥40 years. 72 patients were enrolled, with data analysed for 69 of the patients (mean FEV1 48.7% predicted [17–92%]).6

Trimbow device with close up on the dose counter

For additional information to share with your patients who have been prescribed Trimbow please visit our Trimbow patient and carer site.

AeroChamber Plus® is a registered trademark of Trudell Medical International.
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressurised metered dose inhaler; SPC: Summary of Product Characteristics.

References: 

  1. Trimbow pMDI 87/5/9 Summary of Product Characteristics, Chiesi Limited.
  2. Trimbow NEXThaler 88/5/9 Summary of Product Characteristics. Chiesi Limited.
  3. R3F Market data. IQVIA. MAT April 2021.
  4. AeroChamber Plus® Patient Information Leaflet. Trudell Medical International.
  5. Lareau SC, et al. J Am Acad Nurse Pract. 2012; 24: 113 -120.
  6. Chetta A, et al. BMC Pulm Med. 2021; 21: 65.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.